Synthesis Of Polynucleotides Or Oligonucleotides Patents (Class 536/25.3)
-
Patent number: 9005985Abstract: This invention provides compositions that have a light emitting reporter linked to biomolecules, preferably, nucleotide oligomers. The light reporter particles are silylated and functionalized to produce a coated light reporter particle, prior to covalently linking the biomolecules to the light reporter particle. The light reporter particles of the invention can be excited by a light excitation source such as UV or IR light, and when the biomolecule is DNA, the attached DNA molecule(s) are detectable by amplification techniques such as PCR.Type: GrantFiled: February 7, 2013Date of Patent: April 14, 2015Assignee: APDN (B.V.I.) Inc.Inventors: Thomas Kwok, Benjamin MingHwa Liang, Stephane Shu Kin So
-
Patent number: 8993271Abstract: A nucleic acid molecule can be annealed to an appropriate immobilized primer. The primer can then be extended and the molecule and the primer can be separated from one another. The extended primer can then be annealed to another immobilized primer and the other primer can be extended. Both extended primers can then be separated from one another and can be used to provide further extended primers. The process can be repeated to provide amplified, immobilized nucleic acid molecules. These can be used for many different purposes, including sequencing, screening, diagnosis, in situ nucleic acid synthesis, monitoring gene expression, nucleic acid fingerprinting, etc.Type: GrantFiled: March 14, 2013Date of Patent: March 31, 2015Assignee: Illumina, Inc.Inventors: Eric H. Kawashima, Laurent Farinelli, Pascal Mayer
-
Publication number: 20150087820Abstract: The present disclosure generally pertains to systems and methods for the chemical synthesis of micro-quantities of oligonucleotides or other chemical molecules. The system includes a reusable glass micro-reactor containing a paramagnetic solid support, a magnet, an electronic drive controller and an optical spectroscopy system capable of driving a plurality individual reactors. The system utilizes the electroosmotic movement of reactants through microfluidic channels. Spectrophotometric monitoring of the reaction products allows for the real-time determination of synthesis yield.Type: ApplicationFiled: July 17, 2014Publication date: March 26, 2015Inventors: Lance Amate Larka, John D. Williams, Randy Gaillard
-
Publication number: 20150087070Abstract: Synthetic, derivative promoters for expression of chimeric genes in Zymomonas, Zymobacter, and related bacteria were created. The promoters have a C to T change in the nucleotide at position 90 of the Z. mobilis glyceraldehyde-3-phosphate dehydrogenase gene promoter. Promoters with this change have higher expression as compared to the native promoter from which they are derived and are useful for genetic engineering for expressing coding regions or regulatory RNA to obtain high levels of expressed proteins or regulatory RNAs.Type: ApplicationFiled: September 26, 2013Publication date: March 26, 2015Applicant: E I DU PONT DE NEMOURS AND COMPANYInventor: JIANJUN YANG
-
Patent number: 8987437Abstract: The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties.Type: GrantFiled: May 18, 2012Date of Patent: March 24, 2015Assignee: Gilead Sciences, Inc.Inventors: Richard Hung Chiu Yu, Brandon Heath Brown, Richard P. Polniaszek, Benjamin R. Graetz, Keiko Sujino, Duong Duc-Phi Tran, Alan Scott Triman, Kenneth M. Kent, Steven Pfeiffer
-
Patent number: 8981076Abstract: This invention relates to synthesis of novel -N-FMOC protected nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides and RNA oligonucleotide synthesis. Our discovery using N-FMOC as nucleoside base protecting group, which is highly base labile protecting group is a novel approach to obtain highest purity oligonucleotides. This approach is designed to lead to very high purity and very clean oligonucleotide, after efficient removal of the protecting groups and to produce high purity therapeutic grade DNA oligonucleotides, RNA oligonucleotides, diagnostic DNA, diagnostic RNA for microarray platform. The deprotection of FMOC protecting groups of the natural deoxy and ribonucleosides occurs under very mild deprotection conditions such as mild bases, secondary and tertiary amines for removal of such groups under such conditions would allows synthesis of various DNA and RNA of highest purity for diagnostics and therapeutic application.Type: GrantFiled: November 30, 2009Date of Patent: March 17, 2015Assignee: ChemGenes CorporationInventors: Suresh C. Srivastava, Naveen P. Srivastava
-
Patent number: 8981070Abstract: An oligonucleotide-solid phase conjugate, wherein the solid phase is thiophilic and the oligonucleotide comprises at least one thiooxonucleobase according to Formula I, wherein X is CH or N, R1 is H or NH2, --- indicates a covalent bond, and said oligonucleotide is bound to said solid phase via the sulfur atom of said thiooxonucleotide. Also disclosed are methods for producing such conjugate as well as various uses for such oligonucleotide metal conjugate.Type: GrantFiled: April 19, 2013Date of Patent: March 17, 2015Assignee: Roche Diagnostics Operations, Inc.Inventors: Simone Budow, Ping Ding, Dieter Heindl, Alfons Nichtl, Frank Seela
-
Patent number: 8980584Abstract: This invention relates to improved methods for sequencing and genotyping nucleic acid in a single molecule configuration. The method involves single molecule detection of fluorescent labeled PPi moieties released from NTPs as a polymerase extension product is created.Type: GrantFiled: October 24, 2007Date of Patent: March 17, 2015Assignee: Pacific Biosciences of California, Inc.Inventor: John G. K. Williams
-
Patent number: 8969047Abstract: Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay.Type: GrantFiled: July 24, 2013Date of Patent: March 3, 2015Assignee: Luminex CorporationInventors: Jennifer K. Grenier, David J. Marshall, James R. Prudent, Craig S. Richmond, Eric B. Roesch, Christopher W. Scherrer, Christopher B. Sherrill, Jerod L. Ptacin
-
Patent number: 8951728Abstract: The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of: a) adding a linker molecule L to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added in step c).Type: GrantFiled: October 30, 2013Date of Patent: February 10, 2015Assignee: ChemGene Holding ApSInventor: Peter Birk Rasmussen
-
Publication number: 20150037787Abstract: A mixed polynucleotide includes a first double stranded (ds) portion, a second portion including at least one single stranded (ss) portion, and a third ds portion. The second portion connects the first ds portion and the third ds portion to provide a modified polynucleotide.Type: ApplicationFiled: July 31, 2013Publication date: February 5, 2015Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Binquan Luan, Ajay K. Royyuru, Gustavo A. Stolovitzky, Chao Wang, Deqiang Wang
-
Publication number: 20150038691Abstract: A mixed polynucleotide includes a first double stranded (ds) portion, a second portion including at least one single stranded (ss) portion, and a third ds portion. The second portion connects the first ds portion and the third ds portion to provide a modified polynucleotide.Type: ApplicationFiled: August 28, 2013Publication date: February 5, 2015Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Binquan Luan, Ajay K. Royyuru, Gustavo A. Stolovitzky, Chao Wang, Deqiang Wang
-
Publication number: 20150038555Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.Type: ApplicationFiled: October 20, 2014Publication date: February 5, 2015Inventor: Bob Dale Brown
-
Publication number: 20150038558Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.Type: ApplicationFiled: August 11, 2014Publication date: February 5, 2015Inventors: Katalin Kariko, Drew Weissman
-
Patent number: 8932992Abstract: The present invention relates to a method for synthesizing templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The intion allows the generation of libraries which can be screened for e.g. therapeutic activity.Type: GrantFiled: December 9, 2008Date of Patent: January 13, 2015Assignee: Nuevolution A/SInventors: Henrik Pedersen, Alex Haahr Gouilaev, Thomas Franch, Christian Klarner Sams, Eva Kampmann Olsen, Frank Abilgaard Sløk, Gitte Nystrup Husemoen, Jakob Felding, Lene Hyldtoft, Mads Nørregaard-Madsen, Michael Anders Godskesen, Sanne Schrøder Glad, Thomas Thisted, Per-Ola Freskgård, Anette Holtmann
-
Publication number: 20150011746Abstract: The invention features protected linker compounds which comprise at one terminus a protected amino group and at another other terminus a phosphorous activating group, such as a phosphoramidite group. These protected linker compounds are introduced chemically at the 5?-end of oligonucleotides for the purpose of preparing 5?-amino modified oligonucleotides. After deprotection, the thereby introduced amino group then allows further modification (e.g. attachment of dyes) or immobilization (on surfaces or beads) of the oligonucleotide. Specifically, the presented amino protecting group is designed to provide such protected linker compounds in a solid form, which facilitates efficient purification by precipitation or crystallization and aliquoting for distribution and storage.Type: ApplicationFiled: December 19, 2012Publication date: January 8, 2015Inventors: Stefan Pitsch, Stefan Berger
-
Patent number: 8916694Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for diagnosis and treatment of diseases and conditions associated with expression of apolipoprotein B are provided.Type: GrantFiled: January 28, 2011Date of Patent: December 23, 2014Assignee: Genzyme CorporationInventors: Rosanne M. Crooke, Mark J. Graham, Steven Mah
-
Patent number: 8912317Abstract: Sequences of ribonucleic acid interference molecules are provided. For example, in one aspect, at least one nucleic acid molecule comprising at least one of one or more precursor sequences having SEQ_ID NO: 1 through SEQ_ID NO: 3,197 and one or more corresponding mature sequences having SEQ_ID NO: 3,198 through SEQ_ID NO: 6,565 is provided. Techniques are also provided for regulating gene expression.Type: GrantFiled: July 31, 2008Date of Patent: December 16, 2014Assignee: International Business Machines CorporationInventors: Tien Huynh, Isidore Rigoutsos
-
Patent number: 8906615Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(?O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-aribino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.Type: GrantFiled: February 15, 2013Date of Patent: December 9, 2014Assignee: Geron CorporationInventors: Sergei M. Gryaznov, Ronald G. Schultz
-
Publication number: 20140357700Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: August 19, 2014Publication date: December 4, 2014Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Patent number: 8895723Abstract: Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.Type: GrantFiled: March 18, 2013Date of Patent: November 25, 2014Assignees: Alios BioPharma, Inc., Vertex Pharmaceuticals Inc.Inventors: Vladimir Serebryany, Jyanwei Liu, Leonid Beigelman, Young Chun Jung, Peter Jamison Rose, Shereen Ibrahim, Cavan McKeon Bligh, Luigi Anzalone
-
Patent number: 8894946Abstract: This disclosure provides an integrated and automated sample-to-answer system that, starting from a sample comprising biological material, generates a genetic profile in less than two hours. In certain embodiments, the biological material is DNA and the genetic profile involves determining alleles at one or a plurality of loci (e.g., genetic loci) of a subject, for example, an STR (short tandem repeat) profile, for example as used in the CODIS system. The system can perform several operations, including (a) extraction and isolation of nucleic acid; (b) amplification of nucleotide sequences at selected loci (e.g., genetic loci); and (c) detection and analysis of amplification product. These operations can be carried out in a system that comprises several integrated modules, including an analyte preparation module; a detection and analysis module and a control module.Type: GrantFiled: October 19, 2012Date of Patent: November 25, 2014Assignee: IntegenX Inc.Inventors: William D. Nielsen, Richard J. Belcinski, Gregory Bogdan, David Eberhart, Omar El-Sissi, Stevan B. Jovanovich, Michael Recknor, Ezra Van Gelder, David W. Wyrick
-
Patent number: 8889851Abstract: A reagent for oligonucleotide synthesis or purification, wherein the reagent has a structure of: X—C—L—H??(Formula A) wherein X is a phosphoramidite group, an H-phosphonate group, an acetal group, or an isocyanate; C is a direct bond or a cleavable adaptor represented by —Ca—Cb—; L is a hydrocarbyl chain; and H is a terminal alkyne or an activated cyclooctyne. The reagent of Formula (A) can be used in the synthesis and purification of oligonucleotides.Type: GrantFiled: November 6, 2012Date of Patent: November 18, 2014Assignee: Agilent Technologies, Inc.Inventors: Emily Marine Leproust, Jeremy Lackey
-
Patent number: 8889350Abstract: Methods of isolating target double-stranded polynucleotides with internal single-stranded regions are provided. Compositions and kits comprising double-stranded polynucleotides with internal single-stranded regions are also provided.Type: GrantFiled: March 28, 2011Date of Patent: November 18, 2014Assignee: Swift Biosciences, Inc.Inventor: Vladimir Makarov
-
Publication number: 20140335568Abstract: The present disclosure relates to a nucleic acid assembly (NAA), comprising sensor domain and handle domain; an assembly interfaceable motif (AIM) sequence optionally along with intracellular targeting motif (ITM) sequence; and an AIM-NAA complex. It also relates to a vector comprising assembly interfaceable motif sequence optionally along with intracellular targeting motif sequence and a cell comprising the vector. Further, the instant disclosure also provides a method to obtain the nucleic acid assembly, method of intracellular targeting and kit thereof.Type: ApplicationFiled: October 11, 2012Publication date: November 13, 2014Applicant: NATIONAL CENTRE FOR BIOLOGICAL SCIENCESInventors: Yamuna Krishnan, Souvik Modi
-
Publication number: 20140335630Abstract: Sensors for target entities having functionalized thereon, at least one aptamer specific to the target entity, and methods of making and using the same are described for use in glycated protein monitoring and/or biomarkers.Type: ApplicationFiled: July 31, 2014Publication date: November 13, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Brent D. Cameron, Dong-Shik Kim
-
Patent number: 8883994Abstract: A switch mode nucleic acid aptamer probe includes a probe main body, a fluorescence generating unit and a fluorescence quenching unit which are respectively connected to two ends of the probe main body. The probe main body includes a nucleic acid aptamer fragment with a function of specifically recognizing target tumor cell and a nucleic acid fragment linked to the nucleic acid aptamer fragment by a connection fragment with a length of 7˜15 nm so as to form a hairpin structure. The ability of competitive hybridization of the nucleic acid fragment with the nucleic acid aptamer fragment is weaker than that of the target tumor cell. The use of the probe of the invention can be at least one of specific detection of tumor living cell in buffer solution, effective detection of tumor living cell in serum, and real-time fluorescence imaging and intravital detection of tumor in living body.Type: GrantFiled: March 22, 2011Date of Patent: November 11, 2014Assignee: Hunan UniversityInventors: Kemin Wang, Hui Shi, Xiaoxiao He, Xiaosheng Ye, Xu Wu, Qiuping Guo, Bing Zhou
-
Patent number: 8883455Abstract: An automated method for detecting the presence of a nucleic acid in a sample, where the method is performed within a housing of a self-contained, stand-alone analyzer. The method includes purifying the nucleic acid after it has been immobilized on a magnetically-responsive solid support. A pipette of the analyzer is used to form a reaction mixture comprising the purified nucleic acid and all reagents required to perform a nucleic acid amplification. Amplification products are synthesized that include a nucleotide sequence contained in the nucleic acid or the complement of the nucleic acid. The amplification products are exposed to a probe in a mixture, where the probe forms a hybrid with one of the amplification products. The formation of the hybrid in the mixture provides an indication of the presence of the nucleic acid in the sample.Type: GrantFiled: September 11, 2013Date of Patent: November 11, 2014Assignee: Gen-Probe IncorporatedInventors: Kelly G. Ammann, Ralph E. Burns, Ernest V. Hansberry, Glenn A. Horner, Cheryl A. Jakub, John E. Kling, Donald J. Nieglos, Robert E. Schneider, Robert J. Smith
-
Patent number: 8883516Abstract: The present invention relates to new methods and reagents for coupling molecules by a Click reaction using a heterogeneous catalyst system. Further, the present invention refers to novel devices for carrying out Click reactions.Type: GrantFiled: April 8, 2010Date of Patent: November 11, 2014Assignee: Baseclick GmbHInventors: Antonio Manetto, Philipp Mathias Edwin Gramlich, Simon Warncke
-
Patent number: 8883999Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.Type: GrantFiled: March 17, 2009Date of Patent: November 11, 2014Assignee: Intelligent Bio Systems, Inc.Inventors: Jerzy Olejnik, Evan Guggenheim, Visalakshi Visalakshi
-
Publication number: 20140330002Abstract: A method of forming an end product by self-assembly of a first component having a patch of a linker component, such as DNA strands, cadherins, adhesive proteins and nanoparticle linkers. Such emulsions can be used to process personal care products, skin cremes, foods and animal feedstocks.Type: ApplicationFiled: April 30, 2014Publication date: November 6, 2014Applicant: New York UniversityInventors: Jasna Brujic, Lang Feng, Lea-Laetitia Pontani, Paul Chaikin
-
Publication number: 20140316126Abstract: The invention relates to a method of designing a short RNA molecule to increase the expression of a target gene in a cell through the down-regulation of a non-coding RNA transcript, said method comprising the steps of: a) obtaining the nucleotide sequence of the coding strand of the target gene, at least between 200 nucleotides upstream of the gene's transcription start site and 200 nucleotides downstream of the gene's transcription start site; b) determining the reverse complementary RNA sequence to the nucleotide sequence determined in step a); and c) designing a short RNA molecule which is the reverse complement or has at least 80% sequence identity with the reverse complement of a region of the sequence determined in step b); wherein said method does not include a step in which the existence of said non-coding RNA transcript is determined; and to such short RNA molecules and uses thereof.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventor: Pål Sætrom
-
Patent number: 8859755Abstract: A method for preparing a phosphorothioate RNA based on the oxazaphospholidine method, wherein cyanoethoxymethyl group is used instead of tert-butyldimethylsilyl group as a protective group of 2?-hydroxyl group of RNA.Type: GrantFiled: March 4, 2011Date of Patent: October 14, 2014Assignee: Chiralgen, Ltd.Inventors: Takeshi Wada, Yohei Nukaga
-
Patent number: 8859754Abstract: The present invention is directed towards the synthesis of high purity deuterated sugars, deuterated phosphoramidites, deuterated nucleobases, deuterated nucleosides, deuterated oligonucleotides, and deuterated RNA's of defined sequences which can exhibit biochemically useful and biologically valuable properties, thus having potential for therapeutic uses.Type: GrantFiled: July 31, 2012Date of Patent: October 14, 2014Assignee: Ased, LLCInventors: Suresh C. Srivastava, Amy Yasko
-
Publication number: 20140295447Abstract: The present invention provides a primer set including primers that can be designed easily, with which an amplification distance can be shortened. Provided is a primer set for use in a method for isothermally amplifying a target nucleic acid sequence 4. The primer set includes a first primer 1F and a second primer 1R. The first primer 1F includes, on the 3? side thereof, a sequence (A?) that can hybridize to a sequence (A) on the 3? side of the target nucleic acid sequence. The second primer 1R includes, on the 3? side thereof, a sequence (B?) that can hybridize to a sequence (B) on the 3? side of either a strand extended from the first primer or a complementary strand of the target nucleic acid sequence 4. The first primer 1F and the second primer 1R include, on the 5? sides thereof, sequences (C) that are substantially identical to each other.Type: ApplicationFiled: September 7, 2012Publication date: October 2, 2014Applicants: KABUSHIKI KAISHA DNAFORM, RIKENInventors: Yoshihide Hayashizaki, Yasumasa Kimura, Kengo Usui, Yuki Tanaka, Yuki Kawai
-
Patent number: 8846896Abstract: Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.Type: GrantFiled: March 11, 2013Date of Patent: September 30, 2014Inventors: Vladimir Serebryany, Jyanwei Liu, Leonid Beigelman, Young Chun Jung, Jamison Rose, Shereen Ibrahim, Cavan McKeon, Luigi Anzalone
-
Patent number: 8846885Abstract: The present invention provides a protected nucleotide for elongation, which can be purified efficiently and in a high yield by a liquid-liquid extraction operation, and can achieve an oligonucleotide production method by a phosphoramidite method. It has been found that the above-mentioned problem can be solved by a particular oligonucleotide comprising a protected base and/or particular oligonucleotide protected by a branched chain-containing aromatic group at 3?-position.Type: GrantFiled: February 15, 2013Date of Patent: September 30, 2014Assignee: Ajinomoto Co., Inc.Inventors: Kunihiro Hirai, Satoshi Katayama, Takayoshi Torii, Ryotaro Nakaya, Daisuke Takahashi
-
Patent number: 8846883Abstract: Oligonucleotide chemistry is central to the advancement of core technologies such as DNA sequencing, forensic and genetic analysis and has impacted greatly on the discipline of molecular biology. Oligonucleotides and their analogues are essential tools in these areas. They are often produced by automated solid-phase phosphoramidite synthesis but it is difficult to synthesize long DNA and RNA sequences by this method. Methods are proposed for ligating oligonucleotides together, in particular the use of an azide-alkyne coupling reaction to ligate the backbones of oligonucleotides together to form longer oligonucleotides that can be synthesized using current phosphoramidite synthesis methods.Type: GrantFiled: March 1, 2012Date of Patent: September 30, 2014Assignee: University of SouthhamptonInventors: Tom Brown, Afaf Helmy El-Sagheer
-
Publication number: 20140256881Abstract: The invention provides methods for stably binding and immobilizing deoxyribonucleic acid onto objects and substrates. The method includes exposing the deoxyribonucleic acid to alkaline conditions, and contacting the deoxyribonucleic acid to the object or substrate. The alkaline conditions are produced by mixing the deoxyribonucleic acid with an alkaline solution having a pH of about 9.0 or higher, and contacting the deoxyribonucleic acid to the substrate. The immobilized DNA can be used as a taggant and can be used in combination with other detectable taggants, such as optical reporters. Methods for authentication of a DNA marked object are also provided.Type: ApplicationFiled: March 7, 2013Publication date: September 11, 2014Applicant: APPLIED DNA SCIENCES, INC.Inventor: APPLIED DNA SCIENCES, INC.
-
Patent number: 8822670Abstract: A method of synthesizing a cDNA chain using an insoluble carrier having on the surface thereof a polymer substance containing a first unit having a group derived from a phosphoric ester composing the hydrophilic portion of phospholipid, and a second unit having a group derived from carboxylic acid having an electron-attractive substituent bound to a carbonyl group, which includes immobilizing a polynucleotide for DNA elongation; bringing a solution containing an RNA fragment, nucleotide monomers, and a reverse transcriptase or an enzyme having polymerase activity into contact with the surface of the insoluble carrier; and allowing the polynucleotide for DNA elongation immobilized on the surface of the carrier to elongate using the RNA fragment contained in the solution as a template, to thereby form a single-strand cDNA.Type: GrantFiled: August 9, 2006Date of Patent: September 2, 2014Assignees: Sumitomo Bakelite Company, Ltd., Kenji KinoshitaInventors: Kenji Kinoshita, Toru Yakabe, Kentaro Fujimoto, Kanehisa Yokoyama, Kazuhiko Fujiwara
-
Patent number: 8822671Abstract: A 2?-modified ribonucleoside having an alkoxymethyl protective group can be imparted with a high duplex-forming ability by introducing, as a substituent, a halogen atom into the protective group moiety. A modified form of RNA having a halogen-substituted alkoxymethyl protective group exhibits a high duplex-forming ability that is comparable to the duplex-forming ability of a 2?-O-methyl modified nucleic acid.Type: GrantFiled: November 28, 2011Date of Patent: September 2, 2014Assignees: The University of Tokyo, Chiralgen, Ltd.Inventors: Mamoru Shimizu, Takeshi Wada, Kouichiro Arai
-
Patent number: 8816062Abstract: The compounds of formula (I) substantially in exo form or salts thereof, wherein: X is a biradical selected from —(CH2)n—*, —(CH2CH2O)nCH2CH2—*, methylcyclohexyl and methylphenyl; n is an integer ranging between 1 and 30; Y is a radical selected from —COOH, a substituted phosphoramidite radical and N-hydroxysuccinimide ester (or other active ester) of carboxylic acid; and * represents the place through which X binds to Y, are useful in a general process for solid-phase preparation of maleimide-oligonucleotide derivatives.Type: GrantFiled: May 2, 2011Date of Patent: August 26, 2014Assignee: Universitat de BarcelonaInventors: Ana María Grandas Sagarra, Albert Sánchez González, Enrique Pedroso Muller
-
Patent number: 8809518Abstract: The present invention relates to a linker or population of linkers that include an oligonucleotide fixed portion and an oligonucleotide variable portion represented by formula (N)n, wherein N is A, C, G, T or U, or their derivatives, and n is an integer equal to or higher than 1. A linker-polynucleotide or a population of linker-polynucleotides of the invention may be constituted by said linker or population of linkers and a target first strand polynucleotide bound to said linker. The invention also encompasses a method of preparing said linker or population of linkers and a method of preparing a linker-polynucleotide using said linker or population of linkers. The linkers or polynucleotide-linkers of the invention can be used in a method of preparing a cDNA library.Type: GrantFiled: October 4, 2010Date of Patent: August 19, 2014Assignee: RikenInventor: Yoshihide Hayashizaki
-
Patent number: 8809020Abstract: This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in blood plasma or serum fraction for the detection, monitoring, or evaluation of cancer or premalignant conditions. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.Type: GrantFiled: April 24, 2007Date of Patent: August 19, 2014Assignee: OncoMEDx, Inc.Inventor: Michael S. Kopreski
-
Patent number: 8808986Abstract: Disclosed are methods for synthesizing and/or assembling at least one polynucleotide product having a predefined sequence from a plurality of different oligonucleotides. In exemplary embodiments, the methods involve synthesis and/or amplification of different oligonucleotides immobilized on a solid support, release of synthesized/amplified oligonucleotides in solution to form droplets, recognition and removal of error-containing oligonucleotides, moving or combining two droplets to allow hybridization and/or ligation between two different oligonucleotides, and further chain extension reaction following hybridization and/or ligation to hierarchically generate desired length of polynucleotide products.Type: GrantFiled: August 27, 2009Date of Patent: August 19, 2014Assignee: Gen9, Inc.Inventors: Joseph Jacobson, George Church, Larry Li-Yang Chu
-
Patent number: 8808995Abstract: Methods for genotyping polymorphisms using a locus specific primer that is complementary to a region near a selected polymorphism are described. Methods for synthesizing pools of locus specific primers that incorporate some degenerate positions are also disclosed. A plurality of different sequence capture probes are synthesized simultaneously using degenerate oligonucleotide synthesis. The sequence of the locus specific regions of the capture probes are related in that they have some bases that are identical in each sequence in the plurality of sequences and positions that vary from one locus specific region to another. The sequences are selected based on proximity to a polymorphism of interest and because they conform to a similar sequence pattern.Type: GrantFiled: January 11, 2012Date of Patent: August 19, 2014Assignee: Affymetrix, Inc.Inventors: Ketih W. Jones, Michael H. Shapero, Stephen P. A. Fodor
-
Publication number: 20140228556Abstract: The hammerhead ribozyme according to the present invention produces a hammerhead ribozyme—target RNA construct by base-pairing with an edited target RNA, and an editing recognition site of the hammerhead ribozyme cleaves the modification site by forming a base pair with the target RNA modification site. The cleavage of the modification site is expected to be applicable to the research and development of new drugs that can be used to prevent or treat diseases caused by the edited target RNA.Type: ApplicationFiled: May 19, 2012Publication date: August 14, 2014Applicant: Fukuoka UniversityInventors: Masatora Fukuda, Masanobu Deshimaru, Kei Kurihara
-
Publication number: 20140227280Abstract: The composition includes either an isolated protein complex including MCM8 and MCM9 proteins, or nucleic acid molecules coding for the proteins that constitute the complex, or compounds inhibiting the formation and/or the stability, or the activity of the complex, for its use for enhancing or reducing animal, preferably mammal, fertility.Type: ApplicationFiled: August 30, 2012Publication date: August 14, 2014Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Marcel Mechali, Malik Lutzmann, Sabine Traver, Bernard De Massy, Corinne Grey
-
Patent number: 8802745Abstract: The present invention relates to a porous resin bead containing a first aromatic monovinyl compound-divinyl compound-(meth)acrylonitrile-second aromatic monovinyl compound copolymer, in which the second aromatic monovinyl compound contains a group capable of binding with a carboxyl group by dehydration condensation reaction, and in which the porous resin bead has a swelling volume in acetonitrile of from 3 to 6 ml/g.Type: GrantFiled: September 16, 2010Date of Patent: August 12, 2014Assignee: Nitto Denko CorporationInventors: Kenjiro Mori, Eri Maeta, Tatsuya Konishi
-
Publication number: 20140221454Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a pattern of deoxyribonucleotides (in most embodiments, the pattern comprises at least one deoxyribonucleotide-deoxyribonucleotide base pair) designed to direct the site of Dicer enzyme cleavage within the dsNA molecule. Deoxyribonucleotides of the dsNA molecules of the invention are located within a region of the dsNA that can be excised via Dicer cleavage to generate an active siRNA agent that no longer contains the deoxyribonucleotide pattern (e.g., deoxyribonucleotide-deoxyribonucleotide base pairs). Such DNA-extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be more effective RNA inhibitory agents than corresponding double stranded RNA-extended DsiRNAs.Type: ApplicationFiled: August 20, 2013Publication date: August 7, 2014Applicant: Dicerna Pharmaceuticals, Inc.Inventor: Bob Dale Brown